Recurrent Glioblastoma: Personalized Drug Strategy

We are testing a personalized treatment approach for patients with recurrent glioblastoma to see if tailored drug combinations improve tumor response and overall survival. The study also looks at any side effects from the treatments.

1-2 yearsSafety phase (I)No PlaceboStandard MedicinesInjectionNeurologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Gemcitabine Accord
Gemcitabine Accord is a chemotherapy medicine used to treat several types of cancer, such as pancreatic, lung, bladder, and breast cancer.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Gemcitabine
Gemcitabine is a substance that slows or stops cancer cell growth and is used to treat several cancers, including pancreatic and lung.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Bendacitabin
Demozar
Gemci-Cell

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Oslo University Hospital HF
Department of Neurosurgery
Oslo, Norway
Sponsor: Oslo University Hospital HF
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.